EMA Authorised: Lumigan (bimatoprost) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

The EMA authorised Lumigan (bimatoprost) for open-angle glaucoma and ocular hypertension, with AbbVie Deutschland GmbH & Co. KG as the marketing authorization h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Lumigan (bimatoprost)

Snippet

Status: Authorised. Therapeutic area: Glaucoma, Open-Angle;Ocular Hypertension. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 15/11/2024